This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|June 30, 2022
Getinge Launches New DPTE-EXO with Sleeveless DPTE-BetaBag for Aseptic Transfer
Author(s)BioPharm International Editors
Getinge’s new DPTE-EXO with Sleeveless DPTE-BetaBag is an alpha port with an external opening and an integrated funnel for automated aseptic transfer.
Advertisement
On June 30, 2022, Getinge announced the release of its new DPTE-EXO with Sleeveless DPTE-BetaBag, which offers more secure aseptic transfer. According to a company press release, the product it a first-of-its-kind alpha port that comprises an external opening and an integrated funnel. The design is aimed at securing automated aseptic transfer and improving operational efficiencies.
The new port addresses the need posed by the biopharma industry’s rising demand for throughput and automation as well as stricter good manufacturing practice requirements. The combination of a motorized external-opening alpha port with an optional funnel provides operational efficiency by reducing manual intervention. This design also frees up time for the operator. The product is a fully validated and interlocked system and, with the dismountable funnels, offers a total transfer solution from the outside to the process area. Having the external opening significantly reduces the risk of contamination, and the connectivity offers a greater degree of traceability and data analysis.
“As the industry evolves, the next generation of pharmaceutical manufacturing needs greater flexibility of the batch’s size to switch production quickly from one drug to another,” said Anneke Evers, senior director, DPTE Sales & Market Support, Getinge, in the press release.
“DPTE-EXO with Sleeveless DPTE-BetaBag supports the efforts to build safe, automated, and compliant filling lines. It’s easy to use and has several smart controls governing its safe and efficient door opening and closing and funnel movements. It also integrates a specific program with an open door and funnel position suitable for the barrier system bio-decontamination cycle,” Evers also said in the release.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5